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Chordomas are rare, malignant bone tumors of the skull-base and axial skeleton. Until recently, there was no consensus among
experts regarding appropriate clinical management of chordoma, resulting in inconsistent care and suboptimal outcomes for
many patients. To address this shortcoming, the European Society of Medical Oncology (ESMO) and the Chordoma Foundation,
the global chordoma patient advocacy group, convened a multi-disciplinary group of chordoma specialists to define by consen-
sus evidence-based best practices for the optimal approach to chordoma. In January 2015, the first recommendations of this
group were published, covering the management of primary and metastatic chordomas. Additional evidence and further dis-
cussion were needed to develop recommendations about the management of local-regional failures. Thus, ESMO and CF con-
vened a second consensus group meeting in November 2015 to address the treatment of locally relapsed chordoma. This meet-
ing involved over 60 specialists from Europe, the United States and Japan with expertise in treatment of patients with
chordoma. The consensus achieved during that meeting is the subject of the present publication and complements the recom-
mendations of the first position paper.
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Introduction
Chordomas are rare, malignant bone tumors of the skull-base and
axial skeleton [1]. Loco-regional recurrence is a common event fol-
lowing initial treatment of chordoma patients, and represents a
major clinical challenge, which these recommendations seek to ad-
dress. Loco-regional recurrence is defined as tumor relapse or pro-
gression after surgery and/or RT of the primary tumor at the same
site and/or contiguous spreading of tumor from the primary site
to adjacent areas. This includes progression of treated primary le-
sions, lesions recurring usually at, or near surgical margins, lesions
that develop as a result of iatrogenic seeding along a biopsy or sur-
gical tract, as well as skip metastases in the immediate vicinity of
the tumor. In most cases, spread of the tumor is mediated by direct
physical contact rather than dissemination via lymphatic, circula-
tory or subarachnoid routes. As such, cases with lymph node in-
volvement are considered to have metastatic disease and are thus
not addressed in these recommendations.
Published case series reporting post-surgical outcomes for
chordoma indicate that loco-regional recurrence affects>50% of
patients treated with macroscopic complete resection with or
without RT (Tables 1–3). Notably, a high proportion of recur-
rences occur late (after 5 and 10 years), requiring long-term fol-
low-up [2, 3]. Limited data are available about long-term
recurrence-free survival (RFS), but all available long-term sur-
vival projections do not plateau, even after optimal local therapy.
In particular, RFS or local control (LC) of skull-base chordomas
at 5 and 10 years is 47–76% and 42–71% [3, 4], respectively, while
5- and 10-year estimated RFS for mobile spine chordomas is 58%
and 32% [5]. Similarly, the 5-, 10- and 15-year local relapse (LR)
incidence is reported to be 30%, 46% and 57%, respectively, in a
recently published series of primary and completely resected sa-
cral chordomas [6]. In this study, a plateau in RFS was not
observed even at 15 years.
Major determinants of local control in primary chordomas at
all sites include tumor size, extent of resection, quality of surgery,
quality of RT (e.g. dose, volume, timing and dose inhomogen-
eity) and patient age [2, 7–9]. The experience of the treatment
center may also play a role in the likelihood of recurrence.
Patients whose tumors recur/progress locally are challenging
to control in the long-term and only a minority can be cured.
Hence, every effort is needed to maximize the chances for long-
term control of tumor with optimal management of the patient
at the time of initial treatment. Nevertheless, with optimal treat-
ment, long-term disease control and good quality of life (QOL)
may still be possible for some patients. Thus, defining evidence-
based best practice to manage this disease state is of utmost im-
portance in order to improve patient outcomes.
Methods, level of evidence and grade of
recommendation
To generate the recommendations summarized herein, a consen-
sus group meeting was organized in Milan in November 2015 by
ESMO and the Chordoma Foundation (CF). Representatives
from the all the disciplines involved in care and treatment of pa-
tients with chordoma participated, including specialists in path-
ology, radiology, neurosurgery, ENT surgery, orthopedic surgery,
general surgery, radiotherapy (RT), medical oncology, and pallia-
tive care (PC). A representative from main European, United
States and Japanese RT centers with protons/carbon ions facilities
and with experience in chordoma joined the meeting. Additional
participants included patient representatives, statisticians, and
molecular biologists. Prior to the meeting a literature search was
conducted (details in the supplementary Appendix 1, available at
Annals of Oncology online) to elucidate data upon which to base
consensus recommendations. During the meeting, representa-
tives from 14 of the participating institutions presented unpub-
lished clinical data on patients treated with surgery and/or RT for
recurrent chordoma from 2005. Based on these data and the lit-
erature review, the group reached consensus about key aspects of
the management of patients with loco-regional recurrence, re-
ported in this position paper. The present article is aimed at com-
plementing the recommendations of the first position paper,
published in 2015. To avoid repetition, this text contains several
cross references to it [2].
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We chose to grade level of evidence (LOE) from I to V and
use grades of recommendation from A to D adapted from the
system used by the Infectious Diseases Society of America-US
Public Health Service Grading System 2 (Table 4). When pub-
lished evidence was scarce but a strong consensus was present,
we recorded the LOE as V. Points for which consensus among
participating experts was not achieved are acknowledged an
noted herein. While stronger evidence would be desirable in
many areas, we recognize the inherent difficulty of generating
such data for rare cancers like chordoma, and, thus, accept
that a higher degree of uncertainty must be tolerated for pur-
poses of guideline development to avoid depriving rare cancer
patients and those who care for them of much needed
guidance [10].
Treatment strategy
Figure 1 summarizes the recommended treatment strategy for
patients with loco-regional recurrence.
Table 1. Outcome of patients with recurrent skull-base and cervical spine chordoma and treated with surgical re-resection
Series (REF) Year N. of
patientsa
Location Resection
rate (%)
Complications % Median
follow-up
(years)
1 2 5 10
Recurrence-free survival
(year-survival) (%)
Colli [45] 2001 19 Skull-base T: 31
ST: 16
P: 53
NA 3.2 74 NA 32 NA
Crockard [46] 2001 18 (21) Skull-base and
Cranio-vertebral
junction
T: 72
ST: 33
P: 5
CSF: 55b
Meningitis: 17b
New CN: 5b
Dysphonia: 11b
Pneumonia: 5b
Mortality: 5b
NA NA NA NA NA
Tzortzidis [4] 2006 27 Skull-base GT: 52
ST: 48
NA
D: 4
8 77 52 39 26
Samii [47] 2007 23 Skull-base NA CSF: 0 (0, 12)c
Post-haemorrhage: 0 (10)c
Hydrocephalus: 9 (21)c
Diffuse brain oedema: 0 (5)c
Death for sepsis: 0 (5)c
NA NA NA NA NA
Takahashi [48] 2009 13 Skull-base ST: 46
P: 54
NA 3 NA NA NA –
Sen [49] 2010 12 Craniovertebral
junction
GT: 33 NA 5 NA NA NA –
Koutourousiou [50] 2012 25 Skull-base GT: 44
NT: 20
ST: 16
P: 20
NA NA NA NA NA –
Yasuda [51] 2012 17 Skull-base: 6
Cranio-vertebral
junction: 4
Cervical spine: 7
GT: 47
ST: 53
CSF, meningitis,
hydrocephalus,
CN worsening: 23%
4.7 NA NA (77; 82 PFS) NA
Chibbaro [52] 2014 22 Skull-base GT: 30
ST: 30
P: 40
NA 2.8 NA NA NA –
Boari [53] 2016 13 Clivus GT: 40 NA 6.3 NA NA NA –
Gui [54] 2016 91 Skull-base T: 11
ST: 53
P: 36
NA NA NA NA NA –
Data on the outcome at a longer follow-up are frequently not available since primary and recurrent cases are not analysed separately.
aTotal number of patients with evidence of recurrent chordoma, including those not operated at latest follow-up or dead for disease progression.
bReported for reoperations (ﬁrst and subsequent).
cIn brackets, complication at second and third reoperation.
N of patients, number of patients with chordoma undergoing surgery after initial treatment; REF, reference; N, number; GT, gross total; ST, sub-total;
D, death; NA, not available; CS, cavernous sinus.
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Table 3. Local control of primary and locally recurrent chordoma patients of all sites treated with surgery plus RT or deﬁnitive RT
Series (REF) Year N. pts Type of RT Dose and fractionation Mean FU
(years)
Oncological
outcome
Skull base
Munzenrider [63] 1999 290 Surgeryþprotontherapy
(passive ﬁelds)þphoton
RT
66–83 CGE
Protons 4 fxs/week (1.92
CGE)
Photons 1 fx/week
(1.8 Gy)
3.4 5-year LRFS 73%
chordoma
Noel [64] 2005 88 Surgeryþprotontherapy
(passive ﬁelds)
Median dose 67 CGE
with standard
fractionation
2.6 2-year LC 86%
Ares [65] 2009 41 Surgeryþprotontherapy
(active spot scanning)
Median total dose
73.5 Gy (RBE) with
standard fractionation
3.2 5-year LC—81%
Mizoe [66] 2009 33 Surgeryþcarbon ions (pas-
sive ﬁelds)
Dose escalation 48.0,
52.8, 57.6, and 60.8 Gy
in 16 fractions
4.4 5-year LC—85%
10-year LC—64%
Uhl [61] 2014 155 Surgeryþcarbon ions (ac-
tive spot scanning)
60 Gy RBE
3 Gy RBE per fraction
6 5-year LC—72%
10-year LC—54%
Choy [67] 2016 57 Surgeryþstereotactic radio
surgery (SRS) or stereo-
tactic radiotherapy (SRT)
SRS 17.8 Gy
SRT 63.4 Gy
Hypofractionated
schedule
4.8 Overall LC 48%5-year
PFS 35.2%
Bugoci [68] 2013 12 Surgeryþfractionated
stereotactic
radiotherapy
Median dose 66.6 Gy
with standard
fractionation
3.5 5-year PFS 37.5%
Kano [69] 2011 71 SurgeryþGamma Knife
stereotactic radiosurgery
(SRS)
Median margin dose
15.0 Gy (range 9–
25 Gy)
5 5-year LC 66%
Chang [70] 2001 10 (8 skull
base, 2
cervical spine)
SurgeryþLINAC stereotac-
tic radiosurgery
Mean radiation dose
19.4 Gy
4 Gross LC 80%
Zorlu [71] 2000 18 Surgeryþ3D photons RT Median 60Gy with
standard fractionation
3.6 5-year PFS 23%
Foweraker [72] 2007 12 (10 clivus,
2 cervical spine)
Surgeryþphotons
radiotherapy
65 Gy in 39 fractions 3.2 Gross LC 92%
Sacrum and spine
Imai [62] 2016 188 Exclusive carbon ions (pas-
sive ﬁelds)
Median 67.2 GyE in 16
fractions
5.2
(median)
Primary tumor
10-year OS 69%
5-year LC 77.2%
Recurrent tumor
10-year OS 52%
Uhl [61] 2015 56 (41 primary
tumors, 15
recurrent
tumors)
Carbon ions (active scan-
ning) or photons RT and
carbon ions (active
scanning)6surgery (10
R0/R1 resection 11 R2
resections 20 biopsy
only, 15 recurrences)
Median 66 GyE 2.1 Primary tumor
2-year OS 100%
2-year LC 100%
Recurrent tumor
2-year OS 100%
2-year LC 47%
Mima [73] 2014 23 Exclusive carbon ions or
exclusive protontherapy
70.4 GyE in 16 fractionsor
in 32 fractions
3.2 3-year LC—94%
Rotondo [60] 2015 126 (71 sacrococcygeal,
40 lumbar, 16 thoracic)
Surgeryþprotontherapy Median 72.4 Gy RBE with
standard fractionation
3.5 Primary tumor
5-year OS 81%
5-year LC 68%
Recurrent tumor
5-year OS 78%
5-year LC 49%
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Table 3. Continued
Series (REF) Year N. pts Type of RT Dose and fractionation Mean FU
(years)
Oncological
outcome
Holliday [74] 2015 19 Surgeryþprotontherapy Median 70Gy RBE with
standard fractionation
32.9 2-year LC—58%
DeLaney [59] 2014 29 (23 primary,
6 recurrent)
Surgeryþprotontherapy 77.4 Gy RBE with stand-
ard fractionation
7.3 Primary tumor
5-year LC 100%
8-year LC 92%
Recurrent tumor
5-year LC 50%
Chen [75] 2013 24 (19 sacrum,
2 cervical,
1 thoracic, and
2 lumbar spine)
Exclusive protontherapy
(passive ﬁelds)
77.4 Gy RBE (range 71.6–
79.2 Gy RBE) with
standard fractionation
4.7 5-year LPFS 79.8%
Staab [58] 2011 40 (32 primary,
8 recurrent)
(21 adjuvant RT,
19 macroscopic
disease)
Protontherapy spot
scanning6radical
surgery
72.5 Gy RBE with stand-
ard fractionation
3.6 5-year OS 80%
5-year LC 62%
Dhawale [76] 2014 21 (sacrum) Surgeryþ (18) (3) 3D
conformal RT or IMRT
Mean dose 56Gy with
conventional
fractionation
5.8 Gross LC 60%
Zabel-du Bois [57] 2010 34 First diagnosis: sur-
geryþadjuvant IMRT (13)
or IMRT alone (4)
Recurrent tumor
Surgeryþadjuvant IMRT
(11) or IMRT alone (6)
Mean dose 66Gy with
conventional
fractionation
4.5 Primary tumor
5-year OS 76%
5-year LC 47%
Recurrent tumor
5-year OS 76%
5-year LC 24%
There is no paper speciﬁcally reporting the outcome of relapsed chordoma treated with RT. Most series include both ﬁrst line RT and salvage treatments.
N, number; pts, patients; RT, radiotherapy; FU, follow-up; CGE, cobalt gray equivalent; LRFS, local recurrence-free survival; LC, local control; RBE, relative
biological effectiveness; Gy, Gray; PFS, progression-free survival; GyE, Gray equivalent; OS, overall survival; IMRT, intensity-modulated radiation therapy;
LINAC, linear accelerator; R0, wide resection; R1, marginal resection; R2, intralesional resection.
Table 4. Level of evidence and grade of recommendation
Adapted from the Infectious Diseases Society of American-United States Public Health Service Grading System.
Level of evidence
I. Evidence from at least one large randomized controlled trial of good methodological quality (low potential for bias) or meta-analyses of well
conducted randomized trials without heterogeneity
II. Small randomized trials or large randomized trials with a suspicion of bias (lower methodological quality) or meta-analyses of such trials or of trials
with demonstrated heterogeneity
III. Prospective cohort studies
IV. Retrospective cohort studies or case-control studies
V. Studies without control group, case reports, and experts’ opinions
Grade of recommendation:
A. Strong evidence for efﬁcacy with a substantial clinical beneﬁt, strongly recommended
B. Strong or moderate evidence for efﬁcacy but with a limited clinical beneﬁt, generally recommended
C. Insufﬁcient evidence for efﬁcacy or beneﬁt does not outweigh the risk or the disadvantages (including adverse events and costs), optional
D. Moderate evidence against efﬁcacy or for adverse outcome, generally not recommended
E. Strong evidence against efﬁcacy or for adverse outcome, never recommended
To distinguish prospectively planned studies from retrospective case series, we assigned the level of evidence V followed by ‘*’ to single-group prospective
trials
The guidelines were adapted from the Infectious Diseases Society of America-US Public Health Service Grading System 2
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Patients who experience LR should be evaluated by a multidis-
ciplinary team including at least a medical oncologist, radiothera-
pist, surgeon, pathologist, radiologist and PC specialist with
expertise in chordoma. This recommendation is consistent with
best practice for managing musculoskeletal neoplasms [11].
The presence/absence of symptoms should be factored in the
decision-making algorithm. It is important to involve the patient
when deciding which treatment to pursue.
The ‘extent of local disease’ should be determined using intra-
venous contrast-enhanced MRI. In addition, restaging with total
body computed tomography scan (CT) and whole spine MRI
with a thorough clinical examination should complement loco-
regional assessment to rule out distant metastases and/or sub-
arachnoid spread.
‘Histological confirmation’ of recurrent disease is needed
when there is diagnostic uncertainty, or when there is the suspi-
cion of tumor dedifferentiation (e.g. unusually fast growth), or of
a secondary malignancy. In cases where a tumor relapse is uncer-
tain, a period of observation and re-imaging is an appropriate al-
ternative to histologic assessment. A biopsy can be considered in
selected cases for directing medical therapy.
‘Salvage treatment choices with curative intent’ can include sur-
gery and/or RT, balancing morbidity, QOL and expected disease
control. Surgical and RT strategy should be guided by the nature
and extent of the previous procedure(s), the location of the recur-
rence, tumor resectability, deliverability of RT and the expected
added morbidity of each procedure. Other relevant factors to con-
sider include age, comorbidity, performance status (PS), and status
of the surrounding tissues including the skin. The choice between
surgery alone, surgeryþRT, and RT alone must be based on indi-
vidual case assessment; to date, there are no specific data to back
generalized recommendations. A period of observation and re-
imaging may help select best candidates for resection/RT or both.
In particular, postponing active therapy can be considered in case
of stable disease and/or no progression of symptoms.
The goal of ‘salvage re-resection with curative intent’ should be
to achieve gross total resection, and, when feasible, en-bloc resec-
tion with negative surgical margins (IV-B). The best candidates for
a complete re-resection are patients with isolated disease, a long
disease-free interval, good PS (i.e. Eastern Cooperative Oncology
Group-ECOG PS 2) and with a reasonable likelihood of accept-
able morbidity. In cases of multifocal disease, a cure is virtually im-
possible so re-resection with curative intent should not be
performed (IV-B); in these cases, only a limited resection should be
considered with the goal of preventing the ill effects associated with
disease progression whilst preserving function. A prior history of
piecemeal resection (except for skull-base tumors where resection
may be necessarily piecemeal), prior high-dose RT (in case of mo-
bile spine and sacral chordoma), and/or tumor rupture are obvious
exclusion criteria for re-resection with curative intent (IV-B). There
is no consensus on how to treat intracanalar disease. In patients
who have not previously received high-dose RT at the time of pri-
mary treatment, pre- and/or post-operative treatment with RT may
also be appropriate [12, 13]. This approach is currently the standard
treatment strategy in primary disease at some referral centers [14]
and may be particularly well suited for treating local recurrences as
the chance of achieving a true R0 resection after prior surgical pro-
cedures is low. It is currently not possible to make any recommen-
dations regarding the role of adjuvant re-irradiation after
macroscopically complete resection of recurrent chordoma.
‘Salvage radiotherapy with curative intent’ should be offered
with the same dose and techniques as employed in first-line ther-
apy [2]. Thus, in case of recurrence in patients not previously
treated with RT, definitive RT alone (e.g. without debulking) is a
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reasonable alternative to surgery plus radiation, although neither
is very effective (V-C). Comparative effectiveness data for these
approaches are limited and additional research is needed to de-
termine which approach is superior. Patients considering defini-
tive RT need to be informed about the risk of late toxicities from
high-dose radiation (IV-B).
In the case of recurrent disease after previous RT, a new course
of RT is indicated only when (i) this can be delivered without ex-
ceeding the estimated dose constraints on organs at risk (OARs)
and (ii) adequate coverage of target volumes can be achieved.
If this is not feasible, other treatment modalities are preferable
(V-C). Currently, the cumulative dose tolerance for key OARs
and the potentially protective role of partial damage repair after
the first course of RT are still largely unknown. When complete
resection of a recurrent lesion is not feasible, and proximity to
critical structures precludes adequate RT coverage of target vol-
umes, debulking surgery may be an appropriate option in order
to separate critical structures from the residual tumor, thereby
allowing delivery of a tolerable radiation dose.
‘Salvage palliative/supportive treatment choices’ include debulk-
ing surgery, low-dose RT, stereotactic body RT (SBRT), including
radiosurgery to small volume, radiofrequency ablation (RFA) and
other loco-regional approaches (i.e. cryotherapy), systemic therapy,
PC and observation. The patient’s symptom burden should guide
the selection of an appropriate therapeutic approach as the potential
for cure is nil. Care should be taken to avoid aggressive therapies that
could cause unnecessary additional morbidity. Maximal debulking
surgery should only be considered to alleviate or prevent symptoms
related to nerve/cord/brain compression or for separating vital struc-
tures from the tumor to allow for radiation of the residual disease
(V-C). This type of surgery is indeed only a temporizing measure, as
local disease that remains after surgery will regrow in the region.
Particular caution should be exercised in performing surgery near
prior high-dose RT (IV-C) as the risk of surgical complications is
dramatically greater in this setting. Additionally, the oncologic out-
come generally deteriorates, and the chance of mortality and serious
morbidity increases, with each serial resection (IV-B). Low-dose re-
irradiation with palliative intent can be considered in selected case if
it can be performed with negligible risk of toxicity (V-C).
‘PC’ should be considered as part of the active management of
all patients and should include pain and symptom control, dis-
cussion about a patient’s concerns and wishes, a conversation
about advanced directives, and evaluation of patient and family
psychosocial needs.
‘Salvage palliative anticancer medical therapy’ should be con-
sidered to attempt to stop tumor growth and/or alleviate symp-
toms in cases not amenable to local treatment or when
symptomatic relief is needed, taking into consideration the PS,
co-morbidities, expected treatment-related side effects, and the
patient’s preferences (V*-B).
Technical aspects of treatment
Pre-treatment assessment
Imaging. Any relevant imaging studies performed prior to and
after treatment of the primary chordoma should be obtained and
reviewed. The first post-operative baseline imaging should be
evaluated to confirm the initial extent of resection. Likewise, the
post-radiation imaging at best response should be evaluated to
assess the extent of residual disease. A comparative analysis of the
imaging from first diagnosis to recurrence is important to distin-
guish recurrent disease from treatment sequelae and for assessing
areas at high-risk of microscopic infiltration.
Although MRI is the modality of choice, CT may be a useful
ancillary imaging modality, particularly to assess the bone in-
volvement and when surgical implants or hardware limit MRI re-
liability. Myelo-CT can be useful to visualize peridural spaces
when chordoma tissue invades the spinal canal. Furthermore, CT
is a helpful tool in assessing stability of the spinal column.
For patients with skull-base tumors, assessment of internal ca-
rotid artery (ICA) and/or vertebral arteries with angio-CT can be
needed for surgical planning. If curative surgery is considered,
formal angiography with balloon test occlusion can be considered
if ICA involvement is a limiting factor for tumor resection.
FDG-PET may be used in combination with other modalities
in certain cases to exclude distant relapse and/or to evaluate
tumor activity when tumor dedifferentiation is suspected or if a
lesion is not clearly recurrent tumor.
Pathology. At the time of recurrence, the primary excised chor-
doma sample, including immunohistochemistry for brachyury
and cytokeratin, should be reviewed and confirmed by an expert
pathologist. The diagnosis should be based on the World Health
Organization (WHO) Classification [1].
Tumor biopsy of recurrent disease, when warranted, must be
performed with every attempt to limit the risk of tumor seeding
[2]. A percutaneous core-needle biopsy is the preferable
approach.
If a biopsy is obtained, it should be compared with the primary
tumor to assess whether the tumor has changed or dedifferentiated
over time. Dedifferentiated chordoma can show a deletion of INI1,
which is a potentially targetable molecular alteration [15, 16].
Baseline patient evaluation. Prior to treatment, a complete phys-
ical examination and neurological assessment should be performed.
For skull-base chordomas, endocrinological, ophthalmological and
audiological examination are suggested. The patient’s symptoms
and pace of symptom progression should be noted. Pain assessment
should be performed using a 0–10 pain assessment scale [17].
Chronic pain secondary to RT or surgery should be distinguished
from acute symptoms related to tumor progression for purposes of
considering treatment approaches.
The evaluation should also include a detailed review of notes
describing prior resections and/or RT, including but not limited
to fields, dose and type of RT. The location of previous incisions
or biopsies should be noted in relationship to new tumor le-
sion(s) for purposes of surgical planning.
Resection of recurrent or progressive disease
For mobile spine and sacral tumors, the goal of salvage surgery
with curative intent should be to achieve en-bloc resection with
negative surgical margins (IV-B). Particular attention should be
paid to avoid tumor rupture, as this is associated with significant
risk of tumor seeding. Recurrences in the skull-base or neck, as
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well as in the intrathoracic, intra-abdominal or intra-pelvic areas,
are usually not amenable to margin negative/R0 resections, and
therefore surgery should be aimed at a gross total resection (IV-
B). For skull-base tumors R1 resection should be the goal of sur-
gical treatment in all cases, in order to reduce tumor volume and
increase the effectiveness of subsequent RT (V-A).
Debulking surgery should be cautiously considered only in cer-
tain rare cases, as it is unlikely to prolong survival. When subtotal
resection is performed, every effort should be made to minimize
contamination of the surrounding tissues (V-B).
When no prior RT had been delivered, post-operative RT
should be considered, especially when microscopic margins were
positive/R1. A component of preoperative RT can also be con-
sidered [18].
Radiotherapy of recurrence
RT can be delivered both with curative or palliative intent. To
achieve local control in recurrent chordoma it is necessary to give
a biologically high-dose while limiting the cumulative dose de-
livered to the critical structures near the target volume (IV-B).
The feasibility and utility of RT for patients with recurrent chor-
doma depends primarily on whether or not the patient received
RT to the same area as part of primary management. Thus, rec-
ommendations are presented below for two scenarios: patients
without and with previous irradiation.
RT in patients without previous irradiation. Salvage RT with
curative intent should be offered with the same modality em-
ployed for first line therapy (V-C) [2]. Since chordomas are
radioresistant, a dose of at least 74 GyE should be delivered, using
conventional fractionation (1.8–2 GyE) for photon and proton
therapy (V*-A); moderately hypofractionated schedules can be
used with carbon ions with dose per fractions ranging between 3
and 4.4 Gy RBE and total doses ranging from 60 and 70.4 Gy RBE
[2]. Prior to RT, surgical re-resection should be discussed in all
cases. Target volumes should be delineated considering the pri-
mary tumor location and its recurrence. The high-dose volume
should include any macroscopic disease as well as surgical mar-
gins, while the low-dose volume should encompass areas at risk
of microscopic spread, skip metastases, or seeding due to surgical
procedures. In selected cases, a radio-surgical approach to gross
disease may be appropriate, although there is no consensus as of
yet about the criteria for recommending it.
RT in patients with previous irradiation. The radiation dose pre-
viously received by nearby OARs often limits the dose of radiation
that can be safely delivered to the tumor, making local control of
recurrences challenging. In general, the dose constraints for re-
irradiation to OARs are not clearly established and the degree of re-
covery from initial radiation is difficult to estimate. However, pre-
liminary data are available regarding tolerance to re-irradiation of
the spinal cord, brain and aorta, which can help guide decision-
making [7, 19–22]. If a new course of high-dose RT can be de-
livered without exceeding the estimated dose constraints on OARs,
the patient should be treated with the same intent and approach as
a RT naı¨ve recurrence (V-C). Radiation plans must be based on an
accurate reconstruction of the previous RT dose distribution, and
taking into account expected morbidity of additional radiation
(V-C). In case of tumor seeding in the surgical pathway, the site of
relapse is often outside the previously irradiated volume and can
be adequately treated by radiation [7]. The radiotherapist must ex-
ercise professional judgment in developing the radiation plan, as
there is currently insufficient data to recommend an optimal dose
and fractionation scheme for radiation in this setting. Regardless,
particular caution is warranted in re-irradiating the carotid artery
as severe, life-threatening complications such as carotid blowout
syndrome have been reported in patients treated with re-
irradiation for head and neck cancer [23]. If re-irradiation cannot
achieve sufficiently high-dose or adequate coverage of target vol-
umes without exceeding estimated dose constraints, then other
treatment modalities are preferable. Low-dose re-irradiation with
palliative intent can be appropriate in selected cases but only if it
can be performed with negligible risk of toxicity. The use of high
Linear Energy Transfer (LET) radiation such as carbon ions can be
considered especially in case of re-irradiation after an initial course
of low LET treatment as it may be more effective against the radio-
resistant clones that may have been selected by the first treatment.
Metal implants (e.g. for spine stabilization) complicate RT de-
livery by creating artifacts in CT/MRI images. This can interfere
with precise delineation of target and OAR, especially in the spi-
nal canal. Additionally, these artifacts affect range calculation for
particle therapy, and, therefore, may result in an additional un-
certainty in delivered dose. Consequently, the presence of metal
implants may be a key factor in deciding not to deliver curative
RT or in deciding to deliver it with photons, which are less sensi-
tive to artifacts, instead of particles (IV-B). If a debulking or a
separating surgery is planned, the possibility of modifying,
removing or substituting metal implants with carbon fiber de-
vices should be considered to enable radiation with potentially
curative intent; however, this is appropriate only in very well se-
lected cases after thorough multidisciplinary assessment.
Other local therapies
Retrospective data suggest that cryoablation and RFA can be safe
and useful palliative treatments in recurrent extracranial chordo-
mas with a benefit in pain control [24–26]. However, prospective
studies are needed before recommending these procedures in
chordoma.
SBRT, including radiosurgery, has been described in retro-
spective and prospective series as safe and effective salvage strat-
egy for spine tumors that have recurred after prior RT [27]. SBRT
has been suggested as a palliative treatment option also in chor-
doma patients who suffer LR after prior RT [28], nevertheless
prospective confirmatory data are necessary to make any defini-
tive recommendations.
In principle, other local therapies such as local microwave
hyperthermia and high-intensity focused ultrasound (HIFU)
may also offer benefit in a palliative setting; however, currently
there are no published data supporting their use.
Medical therapy
Medical therapy is an appropriate palliative option for patients
whose disease is actively progressing or who are symptomatic. A
brief observation period may be warranted before starting med-
ical therapy to determine whether, and at what rate, the disease is
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progressing. If no progression is detected, it may be more appro-
priate to continue with active surveillance.
Currently, medical therapy options are limited and no drugs are
approved for the treatment of advanced chordoma. However, sev-
eral targeted therapies have shown modest activity in patients with
recurrent disease. Imatinib and sorafenib are the agents with the
greatest evidence of efficacy in advanced chordoma and represent
reasonable palliative treatment options to slow disease progression
or alleviate symptoms (V*-B) [29–32]. Access to these drugs varies
widely among countries, posing a challenge for patients in some
areas. In addition, several case reports have noted activity of suniti-
nib and EGFR inhibitors (cetuximab, erlotinib, gefitinib) [33–38].
Cytotoxic chemotherapy is generally inactive, and there is in-
sufficient evidence to recommend it (V-D). However, there are
anecdotal reports of responses to chemotherapy in high-grade/
dedifferentiated chordoma and in some pediatric cases [39].
Although no predictors of response to targeted agents have
been identified in chordoma, molecular profiling of tumors may
help guide selection of experimental therapies. One potentially
relevant biomarker is INI1 loss, which has been reported in dedif-
ferentiated chordomas and may confer sensitivity to EZH2 in-
hibitors [15, 16].
A more detailed and up to date description of published data
on medical therapy in chordoma is provided in supplementary
Appendix 2, available at Annals of Oncology online.
Palliative, supportive and end-of-life care
PC is part of the active care of patients with advanced illness [40].
A comprehensive PC approach and access to specialized PC are
both necessary (Table 5) [41].
Most chordoma patients suffer from both somatic and neuro-
pathic pain that can be difficult to treat. Worsening of pain and/or
of neurologic symptoms can be the first sign of disease relapse/pro-
gression even when this cannot be yet detected radiologically [42].
First-line analgesic therapy should be provided by the oncology
team according to available guidelines [43]. Pain due to the compres-
sion of nervous tissues via epidural compression or radiculopathy
often benefits from steroids (dexamethasone or methylpredniso-
lone). Difficult pain syndromes poorly responsive to analgesic
pharmacotherapy can benefit from more invasive analgesic tech-
niques such as spinal administration of opioids, ziconotide and adju-
vant drugs [44].
In the terminal phase, the patient’s preferred setting of care
should be identified. Hospice and home-care are valid options
depending on the patient’s and family’s preferences.
Follow-up
Currently, there is insufficient data to recommend an optimal rou-
tine follow-up policy for patients with recurrent chordoma. Thus,
follow-up is usually chosen based on the best judgment of the pa-
tient’s care team. However, experts agreed that MRI should be per-
formed every 3–6 months at least for the first 3 years from treatment
of LR/local progression. There is currently no consensus about
whether routine scanning of the rest of the body is beneficial and for
how long follow-up should be continued, though long-term vigi-
lance is warranted as relapses often take place after several years.
Emerging approaches and future directions
For those patients who fail surgery and RT, there remains an ur-
gent unmet need for new therapeutic options. To facilitate
Table 5. General schema for palliative care application to advanced chordoma patients
Palliative care domains
• Pain control
• Pain requires careful assessment and classiﬁcation: neuropathic pain is common for chordoma patients and should be correctly diagnosed. The source
of pain should be identiﬁed to help guide pain management; e.g. as a complication of primary disease, as a result of therapy, or as a consequence of
relapse and progression (1).
• Pain management guidelines should be applied by oncology team
• Specialized pain management with medical and anesthesiological procedures may be needed in selected cases (2)
• Control of other symptoms
• Common symptoms requiring management include nausea/vomiting, dyspnea/breathlessness, delirium, anxiety/depression, and other complications
of disease progression
• Prognostication of short-term survival
• Psycological support
• Family-oriented interventions and social support
• End-of-life decisions and palliative sedation
Clinical care pathways and integration with oncology care
• Shared decision-making on goals of management and care should address the following steps:
• Palliative surgical procedures
• Palliative RT or other techniques
• Hydration and nutrition
• Forego or stop antineoplastic treatment
• Advanced directives
• Referral to specialized palliative care should be considered to help with:
• Difﬁcult symptom to control
• Choice of settings of care at the end of life (Hospital, hospice home care) always providing care continuity
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patient participation in clinical trials, the CF maintains an up to
date list of trials open to chordoma patients (www.chordoma
foundation.org/clinical-trials/) and a ‘target dashboard’ (www.
chordomafoundation.org/targets/) summarizing published data
about therapeutically-relevant targets.
Future clinical trials should be designed considering the rarity
and distinctive natural history of chordoma. Due to its rarity,
performing randomized trials may not be feasible. Additionally,
due to its characteristically slow growth-rate and relatively long
expected OS period, determining an OS benefit is likely impracti-
cal, thus necessitating the use of surrogate endpoints to assess ef-
ficacy. However, because patients often experience prolonged
periods of symptomatic disease progression prior to end-stage
disease, conventional surrogate endpoints based solely on dimen-
sional response may miss improvements in QOL, and, thus, may
be inadequate for inferring clinical benefit. New, and possibly un-
conventional, approaches are needed for assessing efficacy and fa-
cilitate the pathway to drug approval. Meanwhile, patients
should be enrolled in prospective registries or observational stud-
ies to better understand the natural history of chordoma and
identify relevant correlates of outcome that could aid in future
trial design and help optimize clinical care.
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